Eloxx Pharma Says ELX-02 Data Showed Increases In Key Metric

Eloxx Pharmaceuticals ELOX shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.

ELX-02 is focused on the development for cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Cystic fibrosis is caused by the absence or dysfunction of a protein called CFTR that controls the movement of salt and water in an out of cells. ELX-02 has shown increased CFTR function in organoids bearing nonsense alleles representing more than 75 percent of the cystic fibrosis nonsense genotype population.

Eloxx will report top-line data from Phase 2 clinical trial in cystic fibrosis later this year. For now, the Phase 2 protocol has been reviewed and approved by the European Cystic Fibrosis Society-Clinical Trial Network and given a score of “high priority.”

On Thursday afternoon, Eloxx Pharmaceuticals shares traded up 25.7 percent to $11.20.

Related Links:

Insys Therapeutics Board Members Resign After $225M DOJ Settlement

ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneralCystic Fibrosis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!